CIA
CLVS

Capital Impact Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Capital Impact Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-21,881
Closed -$1.49M – 157
2017
Q4 		$1.49M Hold
21,881
– – 0.64% 66
2017
Q3 		$1.8M Buy
21,881
+7,843
+56% +$622K 0.81% 35
2017
Q2 		$1.31M Sell
14,038
-5,378
-28% -$329K 0.6% 70
2017
Q1 		$1.24M Buy
+19,416
New +$1.18M 0.49% 114
2015
Q4 		– Sell
-4,656
Closed -$428K – 285
2015
Q3 		$428K Hold
4,656
– – 0.22% 176
2015
Q2 		$409K Hold
4,656
– – 0.19% 211
2015
Q1 		$346K Buy
+4,656
New +$329K 0.16% 226

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Impact Advisors's CLVS Position: Q1 2018 in Review

Capital Impact Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 21,881 shares — an estimated $1.49M sold.

Capital Impact Advisors first reported a position in CLVS in Q1 2015 and held it in 7 quarters. The position peaked at $1.8M in Q3 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

  • Capital Impact Advisors reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
  • Capital Impact Advisors sold 21,881 Clovis Oncology, Inc. shares in Q1 2018, an estimated $1.49M.
  • Capital Impact Advisors first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 7 quarters.
  • Capital Impact Advisors's Clovis Oncology, Inc. position peaked at $1.8M in Q3 2017.
  • 229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Capital Impact Advisors's 13F filing for Q1 2018, filed 11 Apr 2018.